Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 682 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... April 7, 2023 Molecular Burglary: Cancer Cells Hijack Energy from Immune Cells November 21, 2023 Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... September 8, 2020 ¿Pueden confundirse los síntomas del cáncer con la menopausia? November 1, 2022 Load more HOT NEWS News digest – HPV vaccine, 1 million breast screenings missed and... Coronavirus and COVID-19: What People With Cancer Need to Know We want every scientist to thrive in cancer research Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy...
